X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs PANACEA BIOTECH - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER PANACEA BIOTECH PFIZER/
PANACEA BIOTECH
 
P/E (TTM) x 31.0 169.8 18.2% View Chart
P/BV x 4.9 3.8 130.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 PFIZER   PANACEA BIOTECH
EQUITY SHARE DATA
    PFIZER
Mar-16
PANACEA BIOTECH
Mar-14
PFIZER/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,724149 1,831.9%   
Low Rs1,61182 1,957.5%   
Sales per share (Unadj.) Rs440.984.1 524.0%  
Earnings per share (Unadj.) Rs48.7-18.3 -266.0%  
Cash flow per share (Unadj.) Rs75.8-6.7 -1,131.1%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs462.983.7 553.0%  
Shares outstanding (eoy) m45.7561.25 74.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.91.4 358.2%   
Avg P/E ratio x44.5-6.3 -705.5%  
P/CF ratio (eoy) x28.6-17.2 -165.9%  
Price / Book Value ratio x4.71.4 339.3%  
Dividend payout %30.80-   
Avg Mkt Cap Rs m99,1637,074 1,401.7%   
No. of employees `0002.92.8 105.1%   
Total wages/salary Rs m2,7581,449 190.3%   
Avg. sales/employee Rs Th6,981.71,874.1 372.5%   
Avg. wages/employee Rs Th954.5527.0 181.1%   
Avg. net profit/employee Rs Th771.1-407.7 -189.1%   
INCOME DATA
Net Sales Rs m20,1705,154 391.4%  
Other income Rs m857100 859.1%   
Total revenues Rs m21,0285,254 400.3%   
Gross profit Rs m4,310-766 -562.4%  
Depreciation Rs m1,239711 174.2%   
Interest Rs m51,503 0.3%   
Profit before tax Rs m3,923-2,881 -136.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m991,771 5.6%   
Tax Rs m1,79417 10,681.0%   
Profit after tax Rs m2,228-1,121 -198.7%  
Gross profit margin %21.4-14.9 -143.7%  
Effective tax rate %45.7-0.6 -7,842.0%   
Net profit margin %11.0-21.8 -50.8%  
BALANCE SHEET DATA
Current assets Rs m16,2993,810 427.8%   
Current liabilities Rs m7,5948,365 90.8%   
Net working cap to sales %43.2-88.4 -48.8%  
Current ratio x2.10.5 471.2%  
Inventory Days Days65156 41.9%  
Debtors Days Days2667 38.3%  
Net fixed assets Rs m8,62214,480 59.5%   
Share capital Rs m45861 746.3%   
"Free" reserves Rs m20,722903 2,294.6%   
Net worth Rs m21,1805,127 413.1%   
Long term debt Rs m255,832 0.4%   
Total assets Rs m29,13719,433 149.9%  
Interest coverage x755.5-0.9 -82,431.0%   
Debt to equity ratio x01.1 0.1%  
Sales to assets ratio x0.70.3 261.0%   
Return on assets %7.72.0 390.2%  
Return on equity %10.5-21.9 -48.1%  
Return on capital %19.03.6 522.3%  
Exports to sales %0.124.5 0.2%   
Imports to sales %17.510.2 171.7%   
Exports (fob) Rs m121,264 0.9%   
Imports (cif) Rs m3,526525 671.8%   
Fx inflow Rs m521,539 3.4%   
Fx outflow Rs m140942 14.9%   
Net fx Rs m-88597 -14.8%   
CASH FLOW
From Operations Rs m3,436599 573.5%  
From Investments Rs m-6,991-438 1,596.5%  
From Financial Activity Rs m-619-303 204.5%  
Net Cashflow Rs m-4,174-141 2,953.6%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 0.6 1,250.0%  
FIIs % 4.9 1.3 376.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 23.6 100.4%  
Shareholders   85,207 10,259 830.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   IPCA LABS  GSK PHARMA  PLETHICO PHARMA  MERCK LTD  NOVARTIS  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 19, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS